UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

The New England journal of medicine, 2015-04, Vol.372 (16), p.1500-1509

2015

Volltextzugriff (PDF)

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

The New England journal of medicine, 2015-04, Vol.372 (16), p.1489-1499

2015

Volltextzugriff (PDF)

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

The New England journal of medicine, 2014-05, Vol.370 (19), p.1809-1819

2014

Volltextzugriff (PDF)

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

Journal of the American College of Cardiology, 2012-06, Vol.59 (25), p.2344-2353

2012

Volltextzugriff (PDF)

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

The Lancet (British edition), 2012-12, Vol.380 (9858), p.1995-2006

2012

Volltextzugriff (PDF)

Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome

Diabetes, obesity & metabolism, 2017-01, Vol.19 (1), p.98-107

2017

Volltextzugriff (PDF)

Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD

American journal of kidney diseases, 2009-05, Vol.53 (5), p.741-750

2009

Volltextzugriff (PDF)

Anti-PCSK9 Monotherapy for Hypercholesterolemia: The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab

Journal of the American College of Cardiology, 2014-06, Vol.63 (23), p.2531-2540

2014

Volltextzugriff (PDF)

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy

Journal of the American Heart Association, 2015-11, Vol.4 (11)

2015

Volltextzugriff (PDF)

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials

Journal of the American College of Cardiology, 2014-04, Vol.63 (13), p.1278-1288

2014

Volltextzugriff (PDF)

Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease

The American journal of cardiology, 2009-07, Vol.104 (1), p.74-81

2009

Volltextzugriff (PDF)

An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease

Journal of the American College of Cardiology, 2024-05, Vol.83 (20), p.1939-1952

2024

Volltextzugriff (PDF)

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

Circulation (New York, N.Y.), 2014-01, Vol.129 (2), p.234-243

2014

Volltextzugriff (PDF)

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

European heart journal, 2014-09, Vol.35 (33), p.2249-2259

2014

Volltextzugriff (PDF)

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2024-05, Vol.331 (18), p.1534

2024

Volltextzugriff (PDF)

Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus

The American journal of cardiology, 2017-11, Vol.120 (9), p.1521-1527

2017

Volltextzugriff (PDF)

Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics the alliance study

Journal of the American College of Cardiology, 2004-11, Vol.44 (9), p.1772-1779

2004

Volltextzugriff (PDF)

Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia

American journal of health-system pharmacy, 2011-05, Vol.68 (9), p.818-827

2011

Volltextzugriff (PDF)

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina : The Ranolazine Open Label Experience (ROLE)

Journal of the American College of Cardiology, 2007-03, Vol.49 (10), p.1027-1034

2007

Volltextzugriff (PDF)

LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease

Arteriosclerosis, thrombosis, and vascular biology, 2021-12, Vol.41 (12), p.3005-3014

2021

Volltextzugriff (PDF)

Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies

Clinical cardiology (Mahwah, N.J.), 2018-10, Vol.41 (10), p.1328-1335

2018

Volltextzugriff (PDF)

Statin use in a “real-world” clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial

The American journal of medicine, 2005-12, Vol.118 (12), p.16-21

Koren, Michael J.

2005

Volltextzugriff (PDF)

Midwall left ventricular mechanics : an independent predictor of cardiovascular risk in arterial hypertension

Circulation (New York, N.Y.), 1996-01, Vol.93 (2), p.259-265

1996

Volltextzugriff (PDF)

Impact of High‐Dose Atorvastatin in Coronary Heart Disease Patients Age 65 to 78 Years

Clinical cardiology (Mahwah, N.J.), 2009-05, Vol.32 (5), p.256-263

2009

Volltextzugriff (PDF)

Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial

Critical care medicine, 2007-08, Vol.35 (8), p.1863-1868

2007

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(50)

Sprache

Englisch
(50)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(50)
Male
(49)
Middle Aged
(49)
Female
(48)
Life Sciences & Biomedicine
(48)
Science & Technology
(48)
Biological And Medical Sciences
(25)
Cardiovascular System & Cardiology
(24)
Medical Sciences
(24)
Treatment Outcome
(24)
Adult
(23)
Double-Blind Method
(21)
Cardiac & Cardiovascular Systems
(20)
Cholesterol, Ldl - Blood
(20)
Cardiology. Vascular System
(18)
Dose-Response Relationship, Drug
(14)
Hypercholesterolemia - Drug Therapy
(14)
Cardiovascular Disease
(13)
Cholesterol
(13)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome

Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD

Anti-PCSK9 Monotherapy for Hypercholesterolemia: The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials

Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease

An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus

Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics the alliance study

Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina : The Ranolazine Open Label Experience (ROLE)

LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease

Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies

Statin use in a “real-world” clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial

Midwall left ventricular mechanics : an independent predictor of cardiovascular risk in arterial hypertension

Impact of High‐Dose Atorvastatin in Coronary Heart Disease Patients Age 65 to 78 Years

Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial

Aktive Filter

Suchergebnisse filtern